SCHEMBL267963

SCHEMBL267963

CCN(CC)CCN(C)Cc1cccc(C(=O)Nc2ccc(OCCCN3CCCCC3)cc2C(=O)NN)c1

nearest known ligand 0.47

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
BCHE P06276 4/20 0.47
ACHE P22303 4/20 0.47
MET P08581 9/20 0.47
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
NPC1 O15118 1/20 0.42
LMNA P02545 1/20 0.42
MAPK1 P28482 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL267951 0.93 BCHE (0.47) BCHEACHEMETMEN1KMT2A
SCHEMBL267726 0.83 ACHE (0.41) ACHEMEN1KMT2ANPC1LMNA
SCHEMBL274483 0.82 SLC34A2 (0.53) BCHEACHEMETMEN1KMT2A
SCHEMBL268983 0.82 SLC34A2 (0.53) BCHEACHEMETMEN1KMT2A
SCHEMBL268984 0.82 SLC34A2 (0.53) BCHEACHEMETMEN1KMT2A
SCHEMBL267004 0.79 KDR (0.44) BCHEACHENPC1RAB9ASMN1; SMN2
SCHEMBL268050 0.78 ALDH1A1 (0.43) BCHEACHENPC1LMNARAB9A
SCHEMBL15433136 0.76 MAPT (0.42) ACHEMEN1KMT2ANPC1LMNA
SCHEMBL267492 0.76 MET (0.53) METMEN1KMT2ANPC1LMNA
SCHEMBL266705 0.76 ACHE (0.43) BCHEACHENPC1LMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 BCHE 3194/4885ACHE 4048/4885MET 349/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 BCHE 2753/4885ACHE 3423/4885MET 680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.